Good spot kens
Full details here for those interested:
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1="20160184436".PGNR.&OS=DN/20160184436&RS=DN/20160184436
For those wondering how many uses apart from oxycodone, there may be for this matrix patch - the application lists a mind-boggling 49 different classes of suitable biologically active compounds (including anaesthetics; anti-cancer; anti-depressants; anti-diabetics; anti-epileptics; cardiac drugs; statins; ACE inhibitors; anti-alzheimer; opioids, NSAIDS; vaccines and nutraceutical/cosmeceutical active - amongst many others!!).
For those wondering what the current POH matric priorities are:
"Particularly preferred biologically active compounds include alprazolam, donepazil, rispiredone, lorazepam, nicotine, lidocaine, diclofenac, felodipine, insulin, ketoralac, prilocaine, halobetasol, hydrocortisol, opioids such as oxycodone or dihydrohydroxycodeinone (oxycodone base)"
The patent application also details specific laboratory tests for transdermal patch delivery of - insulin; diclofenac; and lidocaine...
hmmm... insulin again after all this time...!!
